United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Altria

Neos S&P 500 High Income ETF

Verizon

Dividend Harvesting Portfolio Week 147: $14,700 Allocated, $1,301.37 In Projected Dividends

Eli Lilly

Eli Lilly is the developer of Mounjaro, a diabetes treatment generating billions in sales. Pfizer has had its challenges as it looks to enter the diabetes and obesity markets.

Interested in the Weight-Loss Market? Here's 1 Stock to Buy Hand Over Fist in 2024, and 1 to Avoid Like the Plague.

Pfizer's COVID-19 product revenue is sinking. Even in a worst-case scenario, though, Pfizer's valuation is much cheaper than its peers.

Could Pfizer Be a No-Brainer Stock to Buy Right Now, Even If Its COVID Sales Continue to Plunge?

Pfizer is one of the largest American pharmaceutical companies, developing medicines and vaccines using cutting-edge technologies to save and improve the lives of millions worldwide. Pfizer's revenue for the three months that ended in 2023 was about $13.23 billion, up 3.9% from the previous quarter, but it missed analysts' expectations by $230 million. On December 14, 2023, Pfizer strengthened its position in the fast-growing cancer drugs market by completing its $43 billion acquisition of Seagen.

The Pfizer Advantage: High Dividend Yield, JN.1 Variant, And Therapeutic Innovations

Apple

ConocoPhillips

D.R. Horton

Netflix

Inundated with myriad ways of assessing publicly traded companies, one unique metric could intrigue investors seeking opportunities in 2024 and that would be high-efficiency stocks. However, rather than focusing on a financial multiple such as sales or earnings, market research specialist Agency Reviews targeted profit per employee.

Top Performers: 7 High-Efficiency Stocks With Stellar Profit Per Employee Ratios

In the most recent trading session, Pfizer (PFE) closed at $28.61, indicating a +0.7% shift from the previous trading day.

Pfizer (PFE) Surpasses Market Returns: Some Facts Worth Knowing

Biogen

Johnson & Johnson

The United States leads globally in the healthcare sector, with its innovative healthcare stocks drawing attention from an impressive $4.3 trillion in spending. As the American Medical Association highlights, this expenditure equals nearly $13,000 per person, contributing 18.3% to the nation's GDP.

Healthcare Heroes: 3 Stocks Innovating in Medicine and Wellness

Alibaba

JD.com

In the dynamic retail and pharma space, the quest for identifying key stocks with promising growth potential is ever-present. Delving into the fundamentals of three corporate giants reveals a strategic blueprint.

The Next Bull Run: 3 Stocks Poised for Unprecedented Growth in 2024

Moderna

Covid-19-vaccine makers Moderna and Pfizer saw shares drop in 2023, but analysts expect double-digit-percentage gains next year.

Moderna and Pfizer Stock Tumbled in 2023. Wall Street Sees a Rebound.

Amgen

Novo Nordisk

Things could hardly have gone worse for healthcare investors this year.

Healthcare Stocks Had a Terrible 2023. Things Are Looking Up.

Pfizer's stock has declined by -44.6% in 2023, but there may be an opportunity for long-term investors due to its current valuation. Pfizer's financials show that it is still profitable and has a strong balance sheet, despite a decline in revenue and profitability. Pfizer backstopped its dividend with a 2.4% increase, indicating confidence in its ability to maintain dividend payments.

Pfizer: Why I Am Buying The 5.92% Yield After The 2.4% Dividend Increase

Bristol-Myers

Chevron

Estee Lauder

NextEra Energy

Exxon Mobil

Investors scored big-time on the biggest S&P 500 stocks this year. But those who picked the wrong stocks suffered mightily.

Investors Lose $426 Billion On These 8 Giant Losers This Year

Danaher

After lagging most sectors in 2023, healthcare stocks could deliver substantial returns in 2024. The market has been overly pessimistic about the sector due to short-term challenges.

Top 3 Healthcare Stock Picks for the New Year

Dollar General

Dollar Tree

Enphase Energy

Walmart

These five S&P 500 stocks have plunged nearly 46% or more in 2023. The reasons behind their declines include macroeconomic factors and falling demand for key products.

Should You Buy This Year's Worst-Performing S&P 500 Stocks for 2024?

Newmont Mining

Vale S.A.

In general, when we talk about 50% to 100% returns in a year, it's associated with growth stocks. However, there are instances where blue-chip stocks outperform backed by valuation factors or some major catalysts.

3 Blue-Chip Stocks Set for a 50% Surge in the Coming Year

Microsoft

NVIDIA

Shopify

Zoom Video

Despite the still-present threat of a recession and the relatively high inflation, 2023 – and especially its later months – brought respite to investors and created room for renewed optimism.

ChatGPT picks 5 stocks to buy for start of 2024

Pfizer is going to see its business slow down next year as the pandemic fades further. If not for its recent acquisition of Seagen, the company's top line would struggle even more in 2024.

Are Investors Overreacting to Pfizer's Underwhelming Forecast for 2024?

Ares Commercial Real Estate

Apollo Commercial Real Estate Finance

British American Tobacco

Blackstone Secured Lending Fund

Cornerstone Strategic Value Fund Inc

Salesforce

Ellington Financial

Energy Transfer LP Unit

Ford Motor Company

FS Credit Opportunities Corp

FS KKR Capital Corp

Modiv

I discuss reader feedback and suggestions regarding the author's daily stock lists and dividend investing strategies. I also address criticisms of preference for low-priced stocks and the debate over whether a $1k investment should exceed the single-share price. Included is a list of the top 10 ReFa/Ro stocks for potential gains in the coming year based on analyst target prices.

November Readers Noted 27 Ideal-To-Buy Dividend Dogs

News for Pfizer Stock (PFE)